Browse > Article
http://dx.doi.org/10.3346/jkms.2018.33.e342

Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer  

Jung, Young Ju (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Oh, In-Jae (Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital)
Kim, Youndong (Aptamer Sciences Inc.)
Jung, Jong Ha (Aptamer Sciences Inc.)
Seok, Minkyoung (Aptamer Sciences Inc.)
Lee, Woochang (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Park, Cheol Kyu (Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital)
Lim, Jung-Hwan (Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital)
Kim, Young-Chul (Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital)
Kim, Woo-Sung (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Choi, Chang-Min (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
Journal of Korean Medical Science / v.33, no.53, 2018 , pp. 342.1-342.6 More about this Journal
Abstract
We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, $AptoDetect^{TM}$-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign nodule controls, 200 participants were enrolled. In a high-risk population corresponding to ${\geq}55years$ of age and ${\geq}30pack-years$, the diagnostic performance was improved, showing 73.3% sensitivity and 90.5% specificity with an area under the curve of 0.88. $AptoDetect^{TM}$-Lung (Aptamer Sciences Inc.) offers the best validated performance to discriminate NSCLC from benign nodule controls in a high-risk population and could play a complementary role in lung cancer screening.
Keywords
Aptamer; Lung Cancer Screening; Lung Nodule; Computed Tomography;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7-30.   DOI
2 Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014;46(2):109-23.   DOI
3 National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395-409.   DOI
4 National Lung Screening Trial Research Team; Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368(21):1980-91.   DOI
5 Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160(5):330-8.   DOI
6 Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ. Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules. Clin Proteomics 2017;14(1):25.   DOI
7 Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000;74(1):5-13.
8 Kanwar JR, Roy K, Maremanda NG, Subramanian K, Veedu RN, Bawa R, et al. Nucleic acid-based aptamers: applications, development and clinical trials. Curr Med Chem 2015;22(21):2539-57.   DOI
9 Yuce M, Ullah N, Budak H. Trends in aptamer selection methods and applications. Analyst (Lond) 2015;140(16):5379-99.   DOI
10 Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010;5(12):e15004.   DOI
11 Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 2010;5(12):e15003.   DOI
12 Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, et al. Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics 2014;11(1):32.   DOI
13 Jung YJ, Katilius E, Ostroff RM, Kim Y, Seok M, Lee S, et al. Development of a protein biomarker panel to detect non-small-cell lung cancer in Korea. Clin Lung Cancer 2017;18(2):e99-107.   DOI
14 Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 2013;5(207):207ra142.   DOI
15 Chong S, Lee KS, Chung MJ, Kim TS, Kim H, Kwon OJ, et al. Lung cancer screening with low-dose helical CT in Korea: experiences at the Samsung Medical Center. J Korean Med Sci 2005;20(3):402-8.   DOI
16 Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e78S-92S.   DOI
17 Smith MA, Battafarano RJ, Meyers BF, Zoole JB, Cooper JD, Patterson GA. Prevalence of benign disease in patients undergoing resection for suspected lung cancer. Ann Thorac Surg 2006;81(5):1824-8.   DOI
18 Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT(R)-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012;33(5):1319-26.   DOI
19 American College of Radiology. Lung CT screening reporting & data system (Lung-RADS). http://www.acr.org/Quality-Safety/Resources/LungRADS. Updated 2014. Accessed July 31, 2014.
20 Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 2013;119(22):3976-83.   DOI